Oral VK2735 · SUNRISE-2
The sponsor announced SUNRISE-1/2 initiation in October 2026. SUNRISE-2 concerns once-daily oral treatment in adults with type 2 diabetes, not the completed VENTURE-Oral Phase 2 result or injected VANQUISH studies. VK2735 — phase 3 study in Weight Loss. NCT07868939 lists Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily as a primary outcome (68 weeks). Registry status: not yet recruiting.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Specify the exact future analysis/cohort and verify that it remains unpublished before creating any tradeable question.
- Registry design and recruitment status are not evidence of efficacy or regulatory approval.
- Primary completion is not a guaranteed topline publication or regulatory decision date.
- Registry primary completion: 2028-10 (estimated); verify independently before using it as a catalyst date.
- An active study record does not establish that its primary outcome is still unannounced. Review sponsor disclosures before promotion to a future catalyst.
Primary evidence
New Phase 3 program — no readout day confirmed
Potential outcome market
Will VK2735 meet the prespecified primary endpoint in NCT07868939 by a listing deadline still to be specified?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.